Against the backdrop of wide variability in thrombotic risk and clopidogrel response in patients following percutaneous coronary intervention (PCI) as well as growing use of more potent antiplatelet ...

The document follows two earlier consensus documents, released in 2013 and 2016. Dominick Angiolillo, MD, PhD (University of Florida College of Medicine – Jacksonville), senior author of the paper, ...

CHICAGO – Among patients with acute coronary syndromes undergoing a procedure such as angioplasty, those who received platelet function tests before receiving antithrombotic therapy to determine ...

April 10, 2009 (Munich, Germany) — A new study using platelet-aggregometry testing to assess the effects of different proton-pump inhibitors (PPIs) on platelet response to clopidogrel suggests that ...

Aspirin is widely prescribed for the secondary prevention of ischemic stroke and acute coronary syndromes, but some patients do not respond to this therapy. There is evidence that these ...

ROME, ITALY — Monitoring platelet function and individualizing antiplatelet therapy did not improve outcomes for elderly ACS patients undergoing coronary stenting, results of the ANTARCTIC trial show ...

An experimental genetic test can gauge a person's risk of developing potentially deadly blood clots, researchers report. People who scored high on the test had more than double the rate of heart ...

Ado-trastuzumab emtansine (T-DM1) treatment results in grade 3-4 thrombocytopenia in 8%-13% of patients. Prior in vitro studies reported T-DM1 inhibition of megakaryocyte maturation as the cause of ...

While thrombocytopenia and bleeding are events that often occur together in neonates, this may not signify cause and effect. In fact, one study reported that 91% of neonates with low platelet counts ...

Managing drug dosage is critical to the overall success of pharmaceutical intervention, not only in the clinic but also in clinical trials. Inadequate dose management of certain drugs can have fatal ...

SAN DIEGO, Oct. 3, 2006 (PRIMEZONE) -- Accumetrics, Inc., a privately held medical device company and maker of the VerifyNow(r) family of diagnostic tests that measure platelet function, today ...